OS Therapies Advances OST-HER2 Toward Accelerated Approval with Elevated FDA Meeting Status
FDA elevated OS Therapies' Type D meeting to Type B pre-BLA meeting for OST-HER2 in osteosarcoma, signaling transition to Accelerated Approval discussions. Clinical data submission targeted for end of Q1 2026.